82.46
전일 마감가:
$83.40
열려 있는:
$83.53
하루 거래량:
300.10K
Relative Volume:
0.56
시가총액:
$5.47B
수익:
-
순이익/손실:
$-224.29M
주가수익비율:
-21.14
EPS:
-3.9
순현금흐름:
$-185.06M
1주 성능:
-2.52%
1개월 성능:
+9.95%
6개월 성능:
+5.34%
1년 성능:
+4.43%
Nuvalent Inc Stock (NUVL) Company Profile
명칭
Nuvalent Inc
전화
508-446-2272
주소
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE
NUVL을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
NUVL
Nuvalent Inc
|
82.46 | 6.07B | 0 | -224.29M | -185.06M | -3.90 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Nuvalent Inc Stock (NUVL) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-03-14 | 업그레이드 | UBS | Neutral → Buy |
2024-12-30 | 개시 | H.C. Wainwright | Buy |
2024-10-24 | 개시 | UBS | Neutral |
2024-08-29 | 개시 | Barclays | Overweight |
2024-04-17 | 개시 | Jefferies | Buy |
2024-04-01 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
2024-02-28 | 재개 | Guggenheim | Buy |
2024-02-23 | 개시 | Robert W. Baird | Outperform |
2023-09-27 | 개시 | Stifel | Buy |
2023-08-08 | 개시 | SVB Securities | Market Perform |
2023-07-24 | 개시 | Guggenheim | Buy |
2023-01-18 | 개시 | Wedbush | Outperform |
2022-06-24 | 개시 | BMO Capital Markets | Outperform |
모두보기
Nuvalent Inc 주식(NUVL)의 최신 뉴스
Nuvalent Initiates Phase 3 ALKAZAR Trial of Neladalkib in NSCLC - Pharmacy Times
Nuvalent begins Phase 3 trial of neladalkib in ALK-positive lung cancer - Investing.com
Nuvalent Initiates Phase 3 ALKAZAR Clinical Trial - TipRanks
Nuvalent doses first patient in phase 3 lung cancer drug trial - Investing.com Australia
Nuvalent announces initiation of Alkazar phase 3 randomized - MarketScreener
Nuvalent Announces Initiation of ALKAZAR Phase 3 Randomized, Controlled Trial Evaluating Neladalkib for Patients with TKI-naïve ALK-positive NSCLC - PR Newswire
Is Nuvalent Inc. a good long term investmentExceptional portfolio growth - PrintWeekIndia
What analysts say about Nuvalent Inc. stockUnbelievable profit margins - PrintWeekIndia
What drives Nuvalent Inc. stock priceOutstanding capital returns - jammulinksnews.com
Nuvalent Inc. Stock Analysis and ForecastBreakthrough financial growth - jammulinksnews.com
How high can Nuvalent Inc. stock price go in 2025Profitable Yet Secure Picks - Newser
Nuvalent(NUVL) Shares Soar 3.01% on Positive Clinical Data - AInvest
Nuvalent, Inc. (NASDAQ:NUVL) Stock Position Decreased by Teacher Retirement System of Texas - Defense World
Why Nuvalent Inc. stock attracts strong analyst attentionDaily Trade Opportunity - Newser
How Nuvalent Inc. stock performs during market volatilityFree Capital Allocation Plans - Newser
What makes Nuvalent Inc. stock price move sharplyFree Access to Stock Community - Newser
Recent Analysts’ Ratings Updates for Nuvalent (NUVL) - Defense World
Insider Selling: Nuvalent, Inc. (NASDAQ:NUVL) Insider Sells $439,890.00 in Stock - Defense World
Nuvalent's Insider Sales and Clinical Milestones: A Balancing Act for Investors - AInvest
Nuvalent(NUVL) Shares Soar 3.47% on Positive Lung Cancer Data - AInvest
Nuvalent Announces Positive Pivotal Data for Zidesamtinib in Lung Cancer - MSN
Nuvalent’s SWOT analysis: biotech stock’s pivotal year ahead By Investing.com - Investing.com Nigeria
Nuvalent’s SWOT analysis: biotech stock’s pivotal year ahead - Investing.com
10 Best High Short Interest Stocks With Huge Upside Potential - Insider Monkey
Nuvalent (NUVL) Gets a Buy from Goldman Sachs - The Globe and Mail
Nuvalent (NASDAQ:NUVL) Upgraded at The Goldman Sachs Group - Defense World
Goldman Sachs initiates coverage on Nuvalent stock with Buy rating By Investing.com - Investing.com India
Goldman Sachs initiates coverage on Nuvalent stock with Buy rating - Investing.com
Nuvalent chief development officer Noci sells $314k in shares - Investing.com
Barclays Sticks to Its Buy Rating for Nuvalent (NUVL) - The Globe and Mail
Nuvalent Believes Safety Profile Can Help Zidesamtinib Be ROS-1 Lung Cancer Leader - insights.citeline.com
Nuvalent (NUVL) Receives Raised Price Target from Baird | NUVL Stock News - GuruFocus
Nuvalent stock price target raised to $114 from $100 at UBS - Investing.com
Data keeps Nuvalent on track for rolling zidesamtinib NDA - The Pharma Letter
Transcript : Nuvalent, Inc.Special Call - MarketScreener
Nuvalent Reports Positive Pivotal Data From ARROS-1 Study Of Zidesamtinib - Nasdaq
Nuvalent Announces Timing of Pivotal Data for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC from ARROS-1 Clinical Trial of Zidesamtinib - Finansavisen
Nuvalent Appoints Christy Oliger to Board of Directors - The Malaysian Reserve
Nuvalent appoints former Genentech oncology executive to board - Investing.com
Nuvalent appoints Christy Oliger to board of directors - MarketScreener
Nuvalent Adds Former Genentech Oncology SVP to Board Ahead of 2026 Launch Plans | NUVL Stock News - Stock Titan
Nuvalent Inc (NUVL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):